DANIEL HOLLOWAY: Open Payments
NPI 1972051522 · RIDGELAND, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,018 in 87 payments from 14 companies in 2025. Trend: 2023 $2,578 · 2024 $2,019 · 2025 $2,018
Food & beverage: $2,018
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $306 |
| Axsome Therapeutics, Inc. | 9 | $295 |
| ABBVIE INC. | 19 | $232 |
| Collegium Pharmaceutical, Inc. | 13 | $208 |
| Otsuka America Pharmaceutical, Inc. | 6 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $157 |
| Tris Pharma Inc | 8 | $152 |
| Supernus Pharmaceuticals, Inc. | 5 | $143 |
| Vanda Pharmaceuticals Inc. | 5 | $127 |
| Corium, LLC | 3 | $70 |
Products named: CAPLYTA, Auvelity, REXULTI, VRAYLAR, Jornay PM, TRINTELLIX, Dyanavel XR, Qelbree.
Industry payments across MS — which companies pay providers there.
